Stepping up behind Sanofi, Genentech rolls the DiCE on a new small molecule discovery pact
Kevin Judice always made a point of staying in touch with some the colleagues he once worked with at Genentech, often bringing them up to speed on the small molecule platform he was building at DiCE Molecules. But he wasn’t quite ready to make any kind of a formal pitch on working together until one of the Bay Area giant’s BD execs came calling recently to get a closer look.
Today, a little less than two years since DiCE Molecules lined up a $2.3 billion discovery pact with Sanofi, heavily weighted to biobucks, the little biotech has come back with its second big alliance with Genentech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.